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1. Introduction  
The hope that delivering genes to ailing tissues and organs can treat disease more effectively 
than drugs or surgery, has fueled the intense interest in gene therapy. Potential uses of gene 
therapy include replacing mutated genes with healthy ones, inactivating improperly 
functioning mutated genes, or introducing new genes into the body to help fight a specific 
disease. While the concept of gene therapy is easy to understand, technical difficulties have 
limited its practical use. Delivered genes that function admirably in cell culture may not 
function correctly in vivo, may have unexpected consequences on intracellular signaling 
pathways, or may transform cells raising the risk of iatrogenic malignancy. 
Retroviruses play a central role in gene delivery applications because they have a high 
infection efficiency and are able to induce stable mutagenesis in eukaryotic cells (Yi et al., 
2005; Somia & Verma, 2000; Thomas et al., 2003). Stable incorporation of retroviral DNA into 
the host genome is advantageous, since long-term expression of the transgene, usually a 
requirement for prolonged therapeutic efficacy, is possible. While they are currently being 
used for in vitro and (animal) in vivo studies, the clinical use of retroviral vectors to deliver 
genes is still in its infancy. Among the reasons for the slow progress in adapting retroviruses 
to deliver genes are the concerns over potential adverse events when introduced into 
humans and a limited understanding of the mechanisms that affect retroviral function and 
expression in infected (target) cells. 
Both wild type and genetically modified retroviruses rely on the host cell to assist during its 
life cycle. Retroviral infection of cells, followed by integration of its genome into the host 
genome, is not always a certain process, however, and cellular and extracellular processes 
can influence these events. Therefore, while retroviral gene delivery is generally successful, 
the impact of viral infections on target cells remains less predictable and can be considered, 
basically uncontrollable. Despite the care with which viral vectors are generated, researchers 
ultimately rely on random events that can yield both positive and negative outcomes. 
In most eukaryotic cells, steroid hormones regulate a wide variety of physiological functions 
ranging from inflammation to pregnancy. There are five major classes of steroid hormones: 
glucocorticoids, mineralocorticoids, estrogens, androgens, and progestins. Steroid hormones 
from each class can complex with their specific receptors, and often with other transcription 
factors, to recognize DNA sequences called response elements. This mechanism of gene 
regulation by steroids is so potent and universal throughout the biosphere that it is not 
surprising that retroviruses have exploited the host nuclear steroid receptor regulatory 
system to expand their own genomes and improve their overall functionality. 
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While most steroid hormone receptor systems could be utilized by retroviruses during 
target cell infection, the strongest evidence exists for an important role of the glucocorticoid 
receptor (GR) in this process. This review focuses on the role of the nuclear glucocorticoid 
receptor in controlling retroviral infection and function and highlights its potential 
importance in retroviral-based gene therapy applications. 
2. Retroviral vectors for gene therapy 
Retroviruses belong to the family Retroviridae which consists of a large and diverse group of 
viruses classified into seven genera. Within each genera retroviruses are structurally and 
functionally similar and further classified based on a computer analysis of their genome. 
Only two of them, gamma-retroviruses and lentiviruses, are commonly used as vectors for 
gene therapy, however. The murine leukemia virus (MLV) is the prototypical gamma-
retroviral backbone that has been modified to generate different gene delivery vectors, 
whereas the human immunodeficiency virus type 1 (HIV-1) provides the standard backbone 
for most lentiviral vectors. Both types of retroviruses (gamma-retroviruses and lentiviruses) 
have been used to generate stable genetic modification in host cells through the 
chromosomal integration of the transferred vector genomes. This ability to stably modify 
target cell genomes is useful not only for research purposes, but also for clinical gene 
therapy strategies intended to correct genetic defects. An important difference between 
gamma-retroviruses and lentiviruses is that gamma-retroviruses can only infect dividing 
cells whereas lentiviruses can infect both dividing and quiescent cells. To date, gamma-
retroviral and lentiviral vectors have been used in more than 300 clinical trials targeting 
various diseases (Telesnitsky, 2010). 
All retroviral genomes are non-segmented and typically consist of at least 4 genes: gag, pro, 
pol and env. The gag gene encodes the major structural polyprotein Gag which is both 
necessary and sufficient for the assembly of non-infectious and immature viral-like particles. 
The pro gene encodes the viral protease that is responsible for facilitating the maturation of 
viral particles. Products of the pol gene include reverse transcriptase, RNase H and 
integrase, all critical for the successful integration of the viral genome into the host genome. 
Env encodes the viral surface glycoprotein and transmembrane proteins that mediate 
cellular receptor binding and membrane fusion. There are additional genes (called accessory 
genes) that are present in some, but not all, gamma-retroviruses and lentiviruses. These 
accessory genes are involved in regulating the synthesis and processing of viral RNA and 
other replicative functions. For the HIV-1 based viruses, these additional genes include: Vif, 
Vpr, Vpu, Tat, Rev, and Nef (Malim & Emerman, 2008). 
The retroviral genome is flanked by two long terminal repeat (LTR) sequences at both the 5’- 
and 3’- ends. In the integrated virus (provirus) each LTR consists of three regions: 1) the R 
sequence, 2) the U3 region, and 3) the U5 region. The R region is a short (18-250nt) sequence 
which forms a direct repeat at both ends of the genome, and is flanked upstream by the U3 
region and downstream by the U5 region in the integrated virus. The U3 is a unique non-
coding segment of 200-1,200nt that forms the 5’ end of the virus after reverse transcription. It 
contains the enhancer elements responsible for transcription of the integrated virus. The U5 
is a unique, non-coding region of 75-250nt which is the first part of the genome to be reverse 
transcribed, forming the 3’ end of the provirus genome. Both U3 and U5 sequences are 
required for viral integration. The Primer Binding Site (PBS) is an 18nt sequence 
complementary to the 3' end of the specific tRNA primer used by the virus to begin reverse 
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transcription. Downstream from the PBS is the packaging signal (psi) sequence that allows 
completed RNA transcripts to be packaged into budding viral cores. Polypurine Tract (PPT) 
is a short (~10nt) run of A/G residues responsible for initiating (+)strand synthesis during 
reverse transcription. The 5’ LTR is the control center for gene expression and contains both 
promoter and regulatory elements that can be responsive to both viral and cellular trans-
activating factors. The 3’ LTR functions as a transcription terminator and a polyadenylation 
signal that leads to the development of a mature viral transcript. 
 
 
Fig. 1. Schematic representation of the retroviral genome. 
For gene delivery applications both gamma-retroviral and lentiviral genomes are initially 
modified to meet certain criteria (Lech & Somia, 2008). This includes removal of gag, pol and 
env to prevent the provirus from generating infectious particles in target cells. This makes 
them safer and therefore more suitable to deliver genes than wild type viruses. Other parts 
of the viral genome, such as PBS and PPT, cannot be removed if the vector is to remain 
functional, however. In addition, while both the LTRs and the psi sequence can be partially 
truncated or modified, they must be present for the virus to function. 
A critical difference therefore, between wild type retroviruses and modified retroviruses 
used in research applications, is the ability of the wild type to generate infectious particles, a 
trait the retroviral vectors lack. The modifications required to make retroviruses safer, 
however, can impact enhancer and promoter elements within the LTR and thus make direct 
comparisons between the behavior of wild type and modified retroviral vectors difficult. 
Specific to this review, modifications within the LTR promoter of both gamma-retroviruses 
and lentiviruses can alter the activity of the nuclear GR-regulatory pathway, yielding 
potentially conflicting experimental results depending on the vector and cell type.  
3. Glucocorticoid receptor regulatory system 
The glucocorticoid receptor (GR) is also known as NR3C1 (nuclear receptor subfamily 3, group 
C, member 1) and is encoded by the NR3C1 gene located on chromosome 5 (5q31) in humans 
(Hollenberg et al., 1985; Francke & Foellmer, 1989; Lu et al., 2006; Rhen & Cidlowski, 2005). The 
GR is expressed in almost every cell in the body and upon binding to glucocorticoids, 
regulates genes controlling development, metabolism, and immune response. 
In the absence of the glucocorticoid hormone, the GR resides, inactive, in the cytosol, 
complexed with a variety of proteins (Pratt et al., 2006). When glucocorticoids bind to the 
GR it can lead to either gene transactivation or gene transrepression (Buckingham, 2006; 
Hayashi et al., 2004). Transactivation usually involves homodimerization of the receptor 
followed by its translocation into the nucleus via active transport. The activated GR binds to 
specific DNA sequences called glucocorticoid response elements (GRE), which are short 
sequences of DNA within the promoter of a gene that are able to bind GR complexes and 
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regulate transcription. The GRE’s sequence is most commonly a pair of inverted repeats 
separated by a short linker, indicating that the receptor binds as a homodimer. Half-sites 
GRE are also present and usually bind monomeric GR. These half-sites are only weakly 
activated by GR complexes, but can also have inhibitory effects, leading to transrepression. 
Nuclear factor-kappaB (NFκB) and the activator protein-1 (AP-1) are two important 
transcription factors that are negatively regulated by the nuclear GR signaling pathway. In 
the absence of activated GR, NFκB and AP-1 are able to translocate into the nucleus and 
transactivate target genes by binding to specific DNA sequences that correspond to each 
transcription factor. Activated GR can complex with either of these transcription factors, 
however, and prevent them from binding their target genes, repressing genes that are 
normally upregulated by NFκB or AP-1. GR-mediated transrepression of NFkB can also 
occur through GR’s binding to NFκB’s response elements, thus preventing transactivation 
(Hermoso & Cidlowski, 2003; Nissen & Yamamoto, 2000; Tuckermann et al., 1999). 
NFkB regulates the expression of well over 100 genes, the majority of which participate in 
the host immune response (Ghosh et al., 1998). These proteins include cytokines and 
chemokines, receptors required for immune recognition, proteins involved in antigen 
presentation, and adhesion receptors involved in transmigration across blood vessel walls. 
Because of its extensive role in immune action, NFkB has been termed the central mediator 
of the immune response (Hiscott et al., 2001). The ability of activated GR to block NFkB’s 
transactivation of these genes is likely important in mediating the immunosuppressive effect 
of glucocorticoids (Ito et al., 2001). 
GRE are present in the genomes of most gamma-retroviruses (Bruland et al., 2003a, 
Rodriguez & Goff, 2010, Pages et al., 1995) and HIV-1 based lentiviruses (Ghosh, 1992; Mitra 
et al., 1995; Hapgood & Tomasicchio, 2010). NFkB response elements are generally absent in 
gamma-retroviruses, but present in HIV-1, making GR-mediated regulation of lentiviral 
vectors derived from the HIV-1 backbone more complex. The presence of GRE and NFkB 
response elements in the retroviral genome suggests that glucocorticoids can exert influence 
on the viral-host cell interaction. Defining the role of GR on the retroviral lifecycle may not 
only provide clues on how to combat retroviral infections, but also provide alternate 
strategies for adapting retroviral vectors for gene delivery. 
4. Effects of activated glucocorticoid receptors on gamma-retroviral and 
lentiviral promoters 
The prominence of GRE in the gamma- and lentiviral genomes suggests that their life cycles 
are dependent on the host’s GR regulatory system (Rusmevichientong & Chow, 2010). 
Glucocorticoids stimulate gamma-retroviral promoter activity in multiple cell types. 
Synthetic corticosteroid hormones stimulated MLV transgene expression in primary bone 
marrow stromal cells (Jaalouk et al., 2000). The synthetic glucocorticoid, dexamethasone, 
increased gamma-retroviral LTR promoter activity in pulmonary artery endothelial and 
smooth muscle cells and also in 293 cells as evidenced by an increased expression of the 
reporter protein, GFP, in infected cells (Solodushko et al., 2009) Most published evidence 
suggests that the usual effect of glucocorticoids on gamma-retroviral promoter activity is 
positive (Mitra et al., 1995). 
The effect of GR on the lentiviral promoter is more complicated than its effect on gamma-
retroviruses, however. Activation of the GR can enhance lentivirus functionality. H9V3 cells 
transfected with the reporter HIV-1 LTR did show increased transgene expression in the 
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presence of glucocorticoids (Kolesnitchenko & Snart, 1992). HIV-1 infected lymphoid and 
monocytoid cell lines treated with cortisol or dexamethasone also increased HIV-1 gene 
expression and virus production in vitro, a process that required the presence of the GRE 
(Soudeyns et al., 1993). In addition, glucocorticoid administration has also been associated 
with increased HIV-1 promoter activity leading to increased virus replication and AIDS 
progression in infected individuals (Kino et al., 2000; Soudeyns et al., 1993). 
 
 
Fig. 2. Schematic representation of binding sites for activated GR in the LTR of MLV (gamma-
retrovirus) and HIV-1 (lentivirus). In MLV GR can bind GRE resulting in transactivation. In 
HIV-l GR can bind GRE1 generally resulting in transactivation and GRE2 and GRE3 (both half 
sites) leading to transrepression. Activated GR can also directly interact with HIV-1 NFkB 
binding sites resulting in transrepression of the viral promoter. 
Lentiviruses contain both stimulatory and inhibitory GRE sites though and therefore 
activated GR can cause different effects depending on the cell type. The first GRE (GRE1) is 
located between −264 and −259 relative to the transcriptional start site and can generally be 
considered a stimulatory GRE. The other GREs (GRE2 and 3) are half sites and are 
positioned between −6 and −1 and between +15 and +20, respectively, relative to the 
transcriptional start site (Mitra et al., 1995; Berkhout et al., 1989). Both GRE half-sites (2 and 
3) are shown to be negative regulators of the viral promoter (Meijsing et al., 2009). 
In addition to its ability to signal through the GRE, the GR signaling pathway can also 
regulate lentiviral (although not gamma-retroviral) behavior through its interaction with the 
NFkB and AP-1 pathway. Activated GR can interfere with NFkB signaling either by directly 
interacting with NFkB response sites or by binding with NFkB proteins (thus blocking its 
ability to enhance the lentiviral LTR). As shown in figure 2 two NFkB response sequences 
(NFkB1) in the HIV-1 U3 region are located between GRE1 and the TATA box. Wild type 
HIV-1 that lacks both of the NFkB binding sites is replication-incompetent; returning one or 
both NFkB elements restores the virus’s ability to replicate (Ross et al., 1991).  
The active binding sites for NFkB, however, are not limited to the enhancing region but can 
be found downstream of the transcription initiation site. In addition to this double NFkB site 
in the U3 region, another double NFkB binding site is present in the R region of the 
lentiviral LTR (NFκB2). This site is also active and contributes to the GR and NFκB response 
and is involved in activating the LTR in response to mitogenic stimuli (Mitra et al., 1995; 
Berkhout et al., 1989; Logan et al., 2004; Kilareski et al., 2009). The p50-p65-NFκB complex 
can bind both of these sites and enhance expression of HIV-1 genes. Further downstream, 
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three AP-1 binding sites in U5 may also potentiate NFkB-dependent responses in integrated 
proviruses (Logan et al., 2004; Kilareski et al., 2009). Figure 2 shows the only direct binding 
sites for GR in retroviral LTR.  
Thus the GR is a regulatory factor that can influence HIV-1 activity through multiple 
mechanisms, not only by its direct binding to the GRE, but also through its effects on NFkB 
and AP-1 signaling pathways. These influences can be both positive and negative. (Hapgood 
& Tomasicchio, 2010; Kino et al., 1999; Ayyavoo et al., 1997a; Mirani et al., 2002) The overall 
effect of glucocorticoids on lentiviral promoter activity, therefore, can be difficult to predict. 
This may explain the confusing, and often contradictory, results on the effect of glucocorticoids 
on HIV-1 progression obtained by different research groups (Kino et al., 2000). 
5. Viral protein R potentiates the effect of glucocorticoid receptor 
In contrast to the relatively simple ways that gamma-retroviruses induce host cell infection, 
lentiviruses have evolved multiple strategies to induce a persistent infection in host cells. 
HIV-1 in particular, employs several strategies that rely on an array of virally encoded 
accessory proteins, including Vif, Vpr, Vpu, and Nef.  Collectively, these proteins appear to 
manipulate host cell biology to ensure a favorable cellular environment for viral replication, 
transmission, dissemination, and immune evasion (Malim & Emerman, 2008). One of them 
in particular, the 14-kDa HIV-1 viral protein R (Vpr), down-regulates the expression of 
genes involved in cell cycle/proliferation, DNA repair, tumor antigen presentation by the 
host cell, and immune activation factors, and upregulates many ribosomal and structural 
proteins required for viral propagation (Janket et al., 2004; Levy et al., 1994; Wu et al., 1995, 
Sherman et al., 2000). These changes can occur in the absence of other viral gene products, 
suggesting that Vpr can mediate its proviral effects partially, or perhaps solely, through 
modulation of the target cell environment (Ayyavoo et al., 1997a). 
Vpr protein is present in high titers in the serum of AIDS patients and can be efficiently 
taken up from the extracellular medium by cells in vitro in a process that occurs independent 
of other HIV-1 proteins and also independent of cellular receptors. Following cellular 
uptake, Vpr can have multiple actions on the host cell GR signaling pathway, an interaction 
that can affect both the host cell and the virus. Two highly conserved leucine-rich domains 
within Vpr resemble the GR coactivator signature motif which allows Vpr to activate the GR 
in the absence in glucocorticoids (Sherman et al., 2000). As a result, the activated Vpr-GR 
complex translocates into the nucleus and induces the expression of glucocorticoid-
responsive genes in a similar direction to that seen with dexamethasone in either the host 
cell or the viral promoters (Muthumani et al., 2006). Vpr can also activate the HIV-1 
promoter without GR, directly binding to the viral SP-1 site in complexes with other 
activators (Kino et al., 2002, Kino et al., 2000, Amini et al., 2004). Thus, Vpr can stimulate the 
retroviral promoter leading to increased virus production and virion maturation. 
Experimentally it has been shown to induce virus expression in the peripheral blood 
mononuclear cells of HIV-infected individuals (Levy et al., 1994) and can directly induce T-
cell receptor-triggered apoptosis. This effect, central to the ability of HIV-1 to deplete T cells, 
can be prevented by the inhibitory steroid hormone mifepristone (Ayyavoo et al., 1997b; 
Fakruddin & Laurence, 2005). In addition to its effect on the lentiviral and the host cell 
promoters, Vpr also enhances expression of the beta-retroviral mouse mammary tumor 
virus (MMTV) promoter suggesting that Vpr could be used as an enhancer in retroviruses 
other than lentiviruses (Kino et al., 2002). 
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Vpr interaction with the host cell’s GR and subsequent ability to transactivate the HIV-1 LTR 
directly (i.e. in the absence of glucocorticoids), can be blocked by mifepristone. Mifepristone, 
also known as RU-486 is an abortifacient that has both anti-progestin and anti-glucocorticoid 
activity. It can bind and activate the GR-alpha primarily, but recent work suggests that it can 
also bind and translocate the GR-beta into the nucleus of Cos1 and U2OS cells, leading to 
upregulation of a number of genes (Lewis-Tuffin et al., 2007). In vitro, mifepristone was able to 
inhibit Vpr-mediated translocation of the HIV nucleoprotein preintegration complex into the 
host cell nucleus and block Vpr-induced apoptosis, cytokine production and T-cell 
proliferation (Schafer et al., 2006). This and other experimental observations led to the 
hypothesis that mifepristone could reduce viral synthesis in infected cells and therefore could 
reduce the pace of infection in vivo. A clinical trial examining the anti-HIV activity and safety 
of mifepristone on viral load, disease progression, and survival in HIV-1 infected individuals 
was begun in 2006 (Clinical trial number: NCT00352911). Final results of that trial have not yet 
been released, but interim results suggest no benefit of mifepristone in the primary endpoint of 
reducing HIV viral load at 28 days (Para et al., 2010).  
6. Role of glucocorticoid receptor in immune resonance, retroviral release 
and integration capability 
Glucocorticoids are among the most commonly prescribed drugs worldwide due to their 
profound anti-inflammatory and immunosuppressive activity (Herold et al., 2006; Kim et 
al., 2001; Janket et al., 2004). They control homeostasis of T cell monocytes/macrophages, 
osteoclasts, and dendritic cells by inducing their apoptosis or inhibiting maturation. Most, if 
not all, of these effects are mediated through their interactions with the GR (Herold et al., 
2006). Activated GR can interfere with the signaling pathways of AP-1 and NFκB, two key 
host transcription factors that regulate expression of pro-inflammatory genes and other 
genes involved in immune responses (Hapgood & Tomasicchio, 2010; De Bosscher et al., 
2003; Smoak & Cidlowski, 2004) 
Vpr enhances the immunosuppressive effect of endogenous and therapeutic glucocorticoids 
(Mirani et al., 2002; Kino et al., 1999). Vpr administered extracellularly potentiated the 
glucocorticoid-induced suppression of mRNA expression and secretion of IL-12 by dendritic 
cells (Kim et al., 2001). Vpr also potentiated the glucocorticoid-induced inhibition of other 
immunologically important cytokines such as IL-2, IL-10, TNF alpha and IL-4, all of which 
are NFκB –dependent (Fakruddin & Laurence, 2005). Both the GR and Vpr are involved in 
the apoptosis in T cells and dendritic cells (Hapgood & Tomasicchio, 2010; Bruland et al., 
2003b). In addition, patients with AIDS and normal cortisol secretion have manifestations 
compatible with glucocorticoid hypersensitivity of the immune system, such as suppression 
of innate and cellular immunity.  
Since the GR plays an important role in regulating viral promoter activity it is not surprising 
that it also affects viral particle production. Dexamethasone can stimulate the gamma-
retroviral promoter in viral producing cells (i.e. HEK 293 packaging cells) significantly 
increasing viral release into the cultured medium, a strategy that can be used to increase the 
viral titer for gene delivery applications (Solodushko et al., 2009). A similar effect can be 
seen with lentiviruses, but this is dependent on the formulation of glucocorticoid used and 
cell type infected. Hydrocortisone increased the efficacy of HIV-1 infection in fresh normal 
human peripheral blood mononuclear leukocytes whereas other corticosteroids 
(dexamethasone) and sex hormones, had no effect (Markham et al., 1986).  
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Fig. 3. A: The anti-glucocorticoid and anti-progestin agent, mifepristone, increased the 
integration efficiency of three gamma-retroviruses: moloney murine leukemia virus (MLV), 
murine stem cell virus (MSCV) and friend murine embryonic stem cell virus (FMEV). Target 
cells included: lung microvascular endothelial cells (expressing both functioning 
glucocorticoid (GR) and progesterone (PR) receptors), U87MG cells (lacking functioning GR) 
and T47D cells (lacking functioning PR). This effect was independent of viral titer. B: 
Infection efficiency of endothelial cells with MLV under four conditions: (C) control, no 
steroid treatment at time of virus propagation and infection; (D) virus was propagated and 
target cells were infected in the presence of glucocorticoid dexamethasone; (M) virus was 
propagated with no steroids and target cells were infected in the presence of mifepristone; 
(D+M) virus was propagated in the presence of dexamethasone followed by infection of 
target cells in the presence of dexamethasone and mifepristone. 
We and others have demonstrated that dexamethasone can stimulate the gamma-retroviral 
LTR promoter and increase viral particle production in packaging cell lines. This effect 
could be blocked by the progestin and glucocorticoid antagonist, mifepristone. In a novel 
observation, we demonstrated that mifepristone could increase the infection efficiency of 
gamma-retroviruses in a number of different target cells including (human, rat, and mouse) 
vascular endothelial and smooth muscle cells, and epithelial cells. This effect was 
independent of viral titer. Later studies demonstrated that mifepristone had no effect on 
viral entry, viral survival or viral DNA synthesis, but increased gamma-retroviral infection 
efficiency by facilitating viral integration into the host genome (figure 3A). This effect 
appeared to be due to mifepristone's anti-glucocorticoid, but not its anti-progestin, activity 
since T47D cells lacking functioning GR did not demonstrate increased infection efficiency 
in the presence of mifepristone, whereas U87MG cells lacking functional progesterone 
receptors, did. Mifepristone had no effect on lentiviral integration into host cells, however. 
These results suggest that inhibition of the GR enhances retroviral integration into the host 
genome and indicates that cells may have a natural protection again retroviral infection that 
may be reduced by glucocorticoid receptor antagonists (Solodushko & Fouty, 2010).  
Based on these observations, we demonstrated that gamma-retroviral infection of target 
cells can be maximized by first incubating packaging cells with dexamethasone to increase 
the viral titre in the supernatant and then incubating target cells with mifepristone to 
improve integration of virus into the host genome (figure 3B) (Solodushko & Fouty, 2010). 
The predominantly cytoplasmic localization of the GR appears to be a specific obstacle for 
HIV replication by preventing its migration into the nucleus where it can complete the 
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infectious process. The presence of both endogenous and exogenous glucocorticoids tends 
to increase the lentiviral infection efficiency of target cells. Resting peripheral mononuclear 
blood cells are not easily infected with HIV-1 due to a block, prior to integration, of the 
provirus into the host genome. Proviral integration increases after addition of a GR ligand 
(such as hydrocortisone or dexamethasone). This effect is confined to an early time period 
after incubation of the cells with the virus and requires the presence of the GR and the GR 
binding viral protein Vpr (Wiegers et al., 2008).  
7. Lessons for retroviral gene therapy 
Due to safety concerns, retroviral vectors are made replication incompetent by the removal 
of the gag, pol and env genes. As a result, while retroviral vectors are still capable of 
transducing cells and expressing the foreign (delivered) gene, they cannot produce 
infectious viral particles due to the lack of structural and enzymatic genes. To generate the 
retroviral vectors needed to deliver genes of interest to target cells, the gag, pol and env genes 
are stably introduced into retroviral-packaging (producing) cells. The presence of 
functioning LTRs, PBS, psi and PPT are required and sufficient for the proper function of 
most gamma-retroviral vectors whereas additional trans and cis elements are required for 
the proper function of lentiviruses. The genetic modifications required to transform wild 
type gamma-retroviruses and lentiviruses into vectors suitable for use in research and 
clinical trials can significantly alter their response to environmental signals. Since the 
retroviral life cycle is dependent somewhat on the function of the GR in host cells, retroviral 
gene delivery vectors derived from wild type retroviruses are also regulated by GR activity. 
While many regions of the wild type retroviral backbones genome can be altered to meet the 
demands of gene delivery, essential parts of the viral genome must be retained to allow 
transgene expression and vector (virus) production. An intact R and U5 regions of the LTR 
promoter are required for the virus to work. Parts of the U3 (enhancer) region of the promoter 
can be modified, deleted or replaced by other sequences, without significantly decreasing 
virus functionality, however. The U3 region of most retroviruses contains GRE and, in the case 
of lentiviruses, NFkB response elements as well. Removing these response elements will still 
allow the virus to function, but will alter its responsiveness to GR signaling pathways. 
Therefore vectors with full length LTR or truncated LTR that retain these GR responsive 
sequences, will behave like wild type viruses in response to GR activation whereas vectors in 
which they have been removed will appear non-responsive to GR activation. 
The promoters of gamma-retroviral vectors with completely functional GRE are strongly 
stimulated when exposed to GR. This enhancing effect of activated GR on the LTR promoter 
in gamma-retroviruses can be exploited to increase viral production by packaging cells and 
also to increase expression of reporter or therapeutic genes in target cells once the viral 
genome is integrated. The net effect of activated GR (due to either glucocorticoids or Vpr) on 
LTR activity in lentiviruses is less predictable, however, due to the opposing effects of GR 
on the GRE and NFkB regulatory segments. Published data indicate that glucocorticoids can 
have either positive or negative effects on the LTR promoter in lentiviruses depending on 
the cell type, glucocorticoid formulation, and vector being studied (Soudeyns et al., 1993; 
Kolesnitchenko & Snart, 1992; Kino et al., 2000; Mitra et al., 1995). 
For the HIV-1 based vector, most of the accessory genes (Vif, Vpr, Vpu, Nef ) as well as Tat 
and Rev have been deleted for safety reasons or separated from the packaging construct. 
Despite these deletions, this modified virus can still function as a gene delivery vector. 
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While the absence of Vpr does not interfere with infection efficiency in most cell types, this 
protein can potentiate transduction of macrophages (Amado & Chen, 1999; Heinzinger et 
al., 1994), muscle, and liver cells (Kafri et al., 1997; Blomer et al., 1997). In addition, Vpr is a 
known activator of lentiviral and cellular promoters and can also enhance activity of the 
MMLV LTR promoter by directly binding to p300/CBP coactivators (Kino et al., 2002). Since 
Vpr is deleted in most lentiviral vectors, its ability to enhance activation of the viral LTR and 
the host promoters is also eliminated. Vpr can enter cells independent of the virus, however, 
and can activate retroviral vectors even if it is not included in the vector. Vpr can block 
NFkB and AP-1 signaling, thus inducing immune suppression which increases the 
likelihood of successful retroviral stable infection of host cells in vivo. When using third 
generation lentiviral vectors which lack Vpr, some investigators have delivered Vpr 
separately to increase the chances of a successful infection.  
Self-inactivating (SIN) retroviral vectors are ones in which a region of the 3’LTR that 
contains an enhancing region of the viral promoter is deleted. The complementary region in 
the 5’LTR is replaced by a promoter to allow transcription of the full-length viral genome. 
After integration into the host genome, the retroviral LTR becomes inactive allowing 
increased transgene expression from another internal promoter. This allows the placement 
of a stronger promoter such as cytomegalovirus (CMV) to increase transgene expression, or 
alternatively, to allow site-specific activation of the transgene such as when the internal 
promoter is the endothelial promoter, Tie2, which will only allow transgene expression in 
endothelial cells.  Originally SIN vectors were thought to be safer for gene therapy because 
they lacked the retroviral enhancer element and therefore do not continue to replicate 
within the host genome. There is some debate about whether this is true or not, however 
(Bosticardo et al., 2009; Yu et al., 1986). 
In SIN vectors, the role of the GR on viral promoter activity is further reduced because the 
GREs within the U3 region are also removed. To combat this limitation, the excised GRE can 
be restored within the second internal promoter. Even without restoring GREs in SIN vectors, 
however, activated GR continue to have an effect on lentiviral behavior due to the presence of 
GRE and NFkB responsive sequences in regions other than U3 (Soudeyns et al., 1993; 
Hapgood & Tomasicchio, 2010; Mitra et al., 1995; Berkhout et al., 1989; Logan et al., 2004; 
Kilareski et al., 2009). GR, in cooperation with other regulatory proteins, can bind these sites 
and enhance AP-1 signaling since several AP-1 binding sites are present not only in U3, but in 
the U5 region of HIV-1 also. Since the R and U5 regions are not significantly altered in 
retroviral vectors due to their importance in viral function, these NFkB and AP-1 sites remain 
relatively intact even in SIN lentiviral vectors and therefore may contribute to residual LTR 
transcriptional activity (Logan et al., 2004; Kilareski et al., 2009; Logan et al., 2004) 
Depending on the type of internal promoter used in SIN vectors, their enhancers may also 
have GRE or NFkB response elements. The most robust and popular internal promoters 
used in lentiviral vectors (such as CMV or SV-40) may also contain NFkB binding sites that 
increase promoter activity when NFkB is bound (Ross et al., 1991). Lentiviral Vpr can also 
increase the activity of CMV, SV-40 and many other internal promoters (Hiscott et al., 2001; 
Roux et al., 2000; Kim et al., 2007). Glucocorticoids can have different effects on these 
internal retroviral promoters if they are used with an intact LTR promoter, however, and 
this appears to be a function of cell type. For example, in bone marrow cells infected with a 
retroviral construction that contains a full length LTR and a second internal SV-40 promoter 
(which does not contain the GRE), dexamethasone suppresses SV-40 promoter activity, 
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whereas in retrovirus-infected fibroblasts infected with the same retroviral vector, 
dexamethasone increased SV-40 activity  (Akahane et al., 2002). Therefore, retroviral vectors 
with internal promoters should be designed individually depending on the cell type that 
needs to be infected and the effect of glucocorticoids on these vectors needs to be tested in 
each cell type.  Understanding the distinct effects of modified vectors in different cell types 
is important for successful gene therapy (Derecka et al., 2006). 
8. Conclusions 
Gamma-retroviruses and lentiviruses are the most commonly used vectors for in vitro and 
in vivo gene delivery and both are responsive to activated GR. The GR signaling pathway is 
an important regulator of retroviral functionality through both its effects on the retrovirus 
and its effects on the target cell. In addition to its effects on the host cell and the retrovirus, 
glucocorticoids and activated GR can also dampen cellular immunity. This is particularly 
important when retroviruses are used as gene delivery vehicles in vivo. Once these wild type 
viruses are modified for gene delivery applications, however, the direction and magnitude 
of this GR response can be altered. Depending on what areas of the retroviral genome are 
changed, the effects of GR activation can vary greatly. In addition, the cell type infected 
contributes to the GR response making predictions about the effects of GR activators (i.e. 
glucocorticoids and Vpr) in specific cell types, difficult. Retroviral vectors therefore, need to 
be designed for a specific purpose and cell type and they must also be tested within the cell 
of interest under the conditions of interest to confirm the desired effect.  
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